

PREOPERATIVE STAGING IN RECTAL CANCER

Jacqueline A. Brown, MD

Department of Radiology
St. Paul's Hospital
Vancouver, BC



Despite potentially curative surgery:

- 30-50% recur
- 1/3 die



BCCA Rectal Cancer Group Guidelines

Clinical Stage 1 (T1, T2, N0, M0)

- Segmental resection. No preop radiation
- Local excision if favorable T1 lesion

Clinical Stage 2 (T3, T4, N0, M0)

- Preop short course radiation
- Segmental resection. Local excision contraindicated

Clinical Stage 3 (any T, N1, N2, N3, M0)

- Managed as for stage 2
- Preop radical preoperative chemoradiation may be indicated

Clinical Stage 4 (any T, any N, M1)

- Excision of primary tumor
- Chemoradiation
- Resection of metastatic lesion
- Fulguration/laser/ endoluminal radiation



RECTAL CANCER STAGING

- **Two consecutive 5 year cohorts of primary rectal cancer surgery.**
- **Periods 1993-1997 and 1998-2002.**
- **Difference between time periods was routine use of pre-operative MR in the second period.**

RECTAL CANCER STAGING

- RO resections increased from 92.5 – 97%.
- Lateral tumor free margin of >1mm increased from 84.4 – 92.1%.

RECTAL CANCER STAGING


- What imaging modality provides the most accuracy for T and N staging?
- What imaging modality provides the most accuracy for the prediction of tumor invasion of the mesorectal fascia?
- Can we abandon routine CT when endorectal US and MR are available?
- What is the present role for PET/CT?

RECTAL CANCER STAGING



- What imaging modality provides the most accuracy for T staging?

5 Layer Model of Rectal Wall

- Balloon interface with mucosa
- Muscularis mucosa
- Submucosa
- Muscularis propria
- Interface of muscularis propria and pararectal fat



Rectal Cancer



Depth of Tumor Invasion

- **Modification of the TNM classification as proposed by Hildebrandt in 1985**
- **Prefix “u” denotes ultrasound staging**

T = Primary Tumor


uTO:

- Noninvasive lesion confined to mucosa

T = Primary Tumor

uT1:


- Invasive tumor confined to the mucosa and submucosa



T = Primary Tumor

uT2:


- Tumor penetrates the muscularis propria but remains confined to the rectal wall



T = Primary Tumor

uT3:


- Tumor penetrates the entire thickness of the bowel wall and invades the perirectal tissues





T = Primary Tumor

uT4:

- Tumor penetrates a contiguous adjacent organ or the pelvic sidewall or sacrum







T4 Lesions

MRI found to be superior to CT in the prediction of organ invasion, pelvic wall invasion, and subtle bone marrow invasion.

Abdom Imaging 2000;25:533-541






Sacral invasion

Wall Penetration

	CT	EUS	MRI
Sensitivity	78%	93%	86%
Specificity	63%	78%	77%
Accuracy	73%	87%	82%

Normal Rectal Wall



RECTAL CANCER STAGING

- Endorectal US is limited by depth of penetration

RECTAL CANCER STAGING

- What imaging modality provides the most accuracy for N staging?

N = Regional Lymph Nodes

NX

Regional lymph nodes cannot be assessed

N0

No regional lymph node metastasis

N1

Metastasis in 1 to 3 regional lymph nodes

N2

Metastasis in 4 or more regional lymph nodes

N3

Metastasis in a lymph node along the course of a named vascular trunk

Nodal Involvement by Tumor


	CT	EUS	MRI
Sensitivity	52%	71%	65%
Specificity	78%	76%	80%
Accuracy	66%	77%	74%

N STAGING


- Differentiation between inflammatory and malignant nodes is imprecise.
- High frequency of micrometastases in normal size nodes in rectal cancer.

Surg Endos 1989;3(2):96-9

Reliability of imaging modalities for predicting lymph node involvement uncertain



Greater than 5 mm = 50-70%



Smaller than 4 mm = 20 % or less



Up to 20% of patients have involved nodes of less than 3mm

Although assessment of T stage is fairly accurate, the assessment of N stage is only moderately effective whatever modality is used.

- **Lack of uniformity for size criteria**
- **Cut off in size not valid**

Regional Lymph Node



N STAGING

- **New ironoxide MR contrast agents (USPIO)**
- **New MR criteria**
 - **Irregular border**
 - **Mixed signal intensity**


Current TNM staging does not quantify the extent of mesorectal invasion.

Radiologists, too, are adopting a **CIRCUMFERENTIAL AWARENESS** in our approach to preoperative staging.

RECTAL CANCER STAGING

- **What modality provides the most accuracy for prediction of tumor invasion of the mesorectal fascia?**

Mesorectal Fascia



CRM

- **92 % agreement between MR images and histologic findings in 98 rectal cancer patients.**

British Journal of Surgery 2003;90:355-64

CRM

- **Accuracy of MRI in prediction of tumor-free resection margin in rectal cancer surgery.**

Lancet 2001;357:497-504


- **Identification of the fascia propria by MRI and its relevance to preoperative assessment of rectal cancer.**

Dis Colon Rectum 2001;44:259-265

- **Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the Mercury Study.**

Radiology 2007; 243(1):132-139

Mesorectal Fascia



CRM

- **Prospective study of 38 patients with a mid or low rectal cancer.**
- **Preoperative MRI.**
- **TME.**

CRM

- **11 mid rectal lesions**
 - **100 % agreement between MR and histologic examination**
- **27 low rectal lesions**
 - **9 anterior (22% agreement)**
 - **18 posterior (83% agreement)**

CRM

- **MRI can overestimate the circumferential resection margin involvement in low anterior tumors.**

CRM

- Anterior perirectal fat is usually very thin.
- Low rectum horizontal in position



CRM

- **Conventional CT for the Prediction of an Involved Circumferential Resection Margin in Primary Rectal Cancer**
 - **Conclusion: Lacks sensitivity for a clinical use in preoperative assessment.**

Dig Dis 2007;25:80-85

CRM

- **Pilot study for multicentric SPICTRE Study**
- **43 patients with rectal cancer**
- **3 observers**
- **Blinded to histological results**
- **Assessed distance to mesorectal fascia**
- **Two categories: <1 or >1 mm**
- **Histology gold standard**

CRM

- **Total of 129 predictions were made:**
 - 26 incorrect (20%)
 - 103 correct (80%)
- **Discrepancies occurred in 11 patients**
 - Poor quality scans (6)
 - Anteriorly located distal tumor (5)

CRM

- **CT has a poor accuracy for predicting MRF invasion in low-anterior located tumors. The accuracy of CT significantly improves for tumors in the mid-high rectum.**

CRM





- **Despite major progress in image quality, CT is still limited by its poor soft tissue contrast resolution.**

CRM

- **MRI is presently considered the best imaging tool for the assessment of the circumferential resection margin.**
- **If MRI is unavailable, CT may be adequate for tumors in the proximal or mid rectum.**
- **MRI should be performed for all tumors in the distal rectum, particularly if located anteriorly.**

CRM


EUS has little to offer as it is limited by its depth of penetration.

- **Can we abandon routine CT of the abdomen and pelvis when endorectal US and high resolution MRI are available?**

Extramesorectal Lymphadenopathy




Enlarged left external iliac node




Enlarged left paraaortic node

Distant Metastases



Enlarged portocaval node



Liver metastasis


PET/CT

- **Has not been systematically assessed as a staging tool for rectal cancer**
- **Highly likely that it will have a role in detecting early recurrence or early metastatic disease**

PET/CT

- **Difficult to monitor for suspected recurrence as other imaging techniques lacked sensitivity and precision, frequently resulting in diagnostic and therapeutic delays**

PET/CT



- ? Tumor recurrence
- ? Postoperative change
- ? Postradiation change

NEGATIVE BIOPSY

PET/CT

- **Able to distinguish benign and malignant presacral abnormalities with a sensitivity, specificity, positive predictive value and negative predictive value of 100%, 96%, 88% and 100% respectively.**

PET/CT

- **Australian PET Data Collection Project**
- **Group A (residual lesion suggestive of recurrent tumor).**
- **Group B (pulmonary or hepatic metastases that were considered potentially resectable).**
- **191 patients**

PET/CT

- **GROUP A**
 - Additional sites of disease detected in 48.4%
 - Change in management documented in 65.6%
- **GROUP B**
 - Additional sites of disease detected in 43.9%
 - Change in management documented in 49.0%

PET/CT

- **Not presently indicated for screening, diagnosis or in those with known disseminated disease**
- **Early detection of recurrent disease**
 - **Prior to curative partial hepatic resection**
 - **Elevated CEA when conventional workup does not indicate site of recurrence**
 - **High risk patient**
 - **Monitoring efficacy of treatment**